drugset / Trial / NCT00441155
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To provide study drug to patients that benefit from treatment judged by the investigator - to obtain additional long-term safety and efficacy data of this combination regimen in GIST
Timeline
- Start
- 2006-11
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 0 mg | Oral |
| Subject | Imatinib | Small molecule | 400 mg | Oral |
| Subject | Imatinib | Small molecule | 600 mg | Oral |
| Subject | Nilotinib | Small molecule | 100 mg | — |
| Subject | Nilotinib | Small molecule | 200 mg | — |
| Subject | Nilotinib | Small molecule | 300 mg | — |
| Subject | Nilotinib | Small molecule | 400 mg | — |